Mammary Cell News Volume 13.46 | Dec 16 2021

    By
    Justin.choi
    -
    0
    42







    2021-12-16 | MCN 13.46


    Mammary Cell News by STEMCELL Technologies
    Vol. 13.46 – 16 December, 2021
    TOP STORY

    Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer

    Lentiviral barcoding/single cell RNA-sequencing revealed that HER2+ breast cancer cells cycled stochastically through a “pre-drug-tolerant persister” state, characterized by a G0-like expression signature and enriched for diapause and/or senescence genes.
    [Cancer Discovery]

    Abstract
    Join us in our mission to advance the pursuit of scientific knowledge by supplying high-quality, innovative reagents, tools and services that enable life science research.
    PUBLICATIONSRanked by the impact factor of the journal

    Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy

    The authors described the synthesis of multiple bromodomain-containing protein 4–casein kinase 2 dual inhibitors based on rational drug design, structure–activity relationship, and in vitro and in vivo evaluations.
    [Journal of the American Chemical Society]

    AbstractGraphical Abstract

    Copper Depletion Modulates Mitochondrial Oxidative Phosphorylation to Impair Triple Negative Breast Cancer Metastasis

    Using two independent TNBC models, researchers reported a discrete subpopulation of highly metastatic SOX2/OCT4+ cells within primary tumors that exhibited elevated intracellular copper levels and a marked sensitivity to tetrathiomolybdate.
    [Nature Communications]

    Full Article

    Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers

    Cell lines grown in vivo more faithfully recapitulated the metabolic profiles of patient tumors compared to those grown in vitro. Integrated metabolic and gene expression analyses identified genes that strongly correlated with metabolic dysregulation and predicted patient prognosis.
    [Cancer Research]

    Abstract

    WNT11/ROR2 Signaling Is Associated with Tumor Invasion and Poor Survival in Breast Cancer

    Scientists modulated the expression of ROR2 in human breast cancer cells and characterized their gene and protein expression by RNA-Seq, qRT-PCR, immunoblots and reverse phase protein array combined with network analyses to understand the molecular basis of ROR2 signaling in breast cancer.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article

    The BH3-Only Protein Noxa Serves as an Independent Predictor of Breast Cancer Patient Survival and Defines Susceptibility to Microtubule Targeting Agents

    The authors identified high NOXA/PMAIP mRNA expression levels as an independent prognostic marker for improved relapse-free survival and overall survival in multivariate analysis in breast cancer patients, independent of their molecular subtype.
    [Cell Death & Disease]

    Full Article

    Transcription Factor FOSL1 Enhances Drug Resistance of Breast Cancer Through DUSP7-Mediated Dephosphorylation of PEA15

    FOSL1 expression in doxorubicin-resistant breast cancer (BC) cells was examined through RT-qPCR, and its influence on the drug resistance of BC cells was explored through a series of in vitro and in vivo mechanism assays.
    [Molecular Cancer Research]

    Abstract

    MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer

    Scientists demonstrated that overexpression of G protein–coupled receptors implicated in breast cancer pathogenesis, specifically the receptors for Angiotensin II and thrombin, drove a strong epithelial-to-mesenchymal transition program in breast cancer cells that was characteristic of claudin-low, TNBC.
    [Molecular Cancer Research]

    AbstractGraphical Abstract

    STAT1 Mediated Long Non-Coding RNA LINC00504 Influences Radio-Sensitivity of Breast Cancer via Binding to TAF15 and Stabilizing CPEB2 Expression

    From RT-qPCR analysis, long intergenic non-protein coding RNA 0504 (LINC00504) was found to be up-regulated in breast cancer (BC) cells. By conducting in vitro assays, researchers confirmed that the knockdown of LINC00504 could enhance the radio-sensitivity of BC cells.
    [Cancer Biology & Therapy]

    Abstract

    The Role of AKR1 Family in Tamoxifen Resistant Invasive Lobular Breast Cancer Based on Data Mining

    Scientists explored the role of aldo-keto reductase family 1 (AKR1) family in tamoxifen-resistant aggressive lobular breast cancer based on data mining.
    [BMC Cancer]

    Full Article
    Guide to everything you need to know about cell separation.
    REVIEWS

    Chitosan: A Versatile Bio-Platform for Breast Cancer Theranostics

    Investigators discuss the application of chitosan as an anticancer drug carrier such as tamoxifen, doxorubicin, paclitaxel, docetaxel, etc. and also, its role as a theranostics moieties.
    [Journal of Controlled Release]

    AbstractGraphical Abstract

    Raman Spectroscopy: Current Applications in Breast Cancer Diagnosis, Challenges and Future Prospects

    The authors explore the application of Raman spectroscopy in breast cancer, including discussion on its capabilities in analyzing both ex vivo tissue and liquid biopsy samples, and its potential in vivo applications.
    [British Journal of Cancer]

    Full Article

    Cell Line-Directed Breast Cancer Research Based on Glucose Metabolism Status

    Studying and identifying distinct metabolic alterations in breast cancer subtypes could offer new perspectives for faster diagnosis and treatment. The metabolic status with emphasis on glycolysis of breast cancer cell lines according to their classification was reviewed.
    [Biomedicine & Pharmacotherapy]

    Full ArticleGraphical Abstract
    INDUSTRY AND POLICY NEWS

    HiberCell to Collaborate with Merck on Phase II Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Metastatic Breast Cancer

    HiberCell announced a clinical trial collaboration with Merck. This metastatic breast cancer clinical trial evaluates KEYTRUDA®, Merck’s anti-PD-1 therapy, in combination with HiberCell’s odetiglucan, a Dectin-1, pattern recognition receptor agonist.
    [HiberCell, Inc.]

    Press Release
    FEATURED EVENT

    AACR: Precision Prevention, Early Detection, and Interception of Cancer

    January 21 -23, 2022
    Austin, Texas, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position- Cell and Chemical Biology

    Leiden University – Leiden, United Kingdom

    Scientific Officer – Functional Genomics

    Institute of Cancer Research – London, United Kingdom

    Research Associate – Molecular Basis of RTK Signaling

    The University of Manchester – Manchester, United Kingdom

    Postdoctoral Research Fellow – Bioinformatics

    The University of British Columbia – Vancouver, British Columbia, Canada

    Postdoctoral Fellow – Translational Cancer Research

    Icahn School of Medicine at Mount Sinai – New York City, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter